Circulating tumor DNA as prognostic marker in patients with metastatic colorectal cancer undergoing systemic therapy: A systematic review and meta-analysis
Open Access
- 24 July 2025
- journal article
- review article
- Published by Elsevier in Cancer Treatment Reviews
- Vol. 139, 102999
Abstract
No abstract availableKeywords
Funding Information
- European Commission (101080009)
This publication has 116 references indexed in Scilit:
- Circulating tumor DNA (ctDNA) trajectories predict survival in trifluridine/tipiracil‐treated metastatic colorectal cancer patientsMolecular Oncology, 2025
- Evaluation of circulating tumor DNA as a prognostic and predictive biomarker in BRAFV600E mutated colorectal cancer—results from the FIRE‐4.5 studyMolecular Oncology, 2024
- Monitoring levels of circulating cell‐free DNA in patients with metastatic colorectal cancer as a potential biomarker of responses to regorafenib treatmentMolecular Oncology, 2021
- Detection of tumor‐derived cell‐free DNA from colorectal cancer peritoneal metastases in plasma and peritoneal fluidThe Journal of Pathology: Clinical Research, 2021
- Plasma clearance ofRASmutation under therapeutic pressure is a rare event in metastatic colorectal cancerInternational Journal of Cancer, 2019
- RAS and BRAF mutations in cell‐free DNA are predictive for outcome of cetuximab monotherapy in patients with tissue‐tested RAS wild‐type advanced colorectal cancerMolecular Oncology, 2019
- Efficacy of Sym004 in Patients With Metastatic Colorectal Cancer With Acquired Resistance to Anti-EGFR Therapy and Molecularly Selected by Circulating Tumor DNA AnalysesJAMA Oncology, 2018
- Serial profiling of circulating tumor DNA for optimization of anti‐VEGF chemotherapy in metastatic colorectal cancer patientsInternational Journal of Cancer, 2017
- Methylated free‐circulating HPP1 DNA is an early response marker in patients with metastatic colorectal cancerInternational Journal of Cancer, 2017
- Changes in mutational status during third‐line treatment for metastatic colorectal cancer—Results of consecutive measurement of cell free DNA, KRAS and BRAF in the plasmaInternational Journal of Cancer, 2014